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SUPPLEMENTAL METHODS 
 
Description of study cohorts 
The following studies included in the current analysis have been described elsewhere: the Age, 
Gene/Environment Susceptibility Study (AGES) Reykjavik study,1 the Arrhythmia-Biobank-
LMU (AFLMU, formerly known as AFNET) and the Cooperative Health Research in the Region 
of Augsburg (KORA),1 the Atherosclerosis Risk in Communities (ARIC) study,1 Cleveland Clinic 
Lone Atrial Fibrillation GeneBank Study (CCAF),1 the Cardiovascular Health Study (CHS),1 
Framingham Heart Study (FHS),1 Massachusetts General Hospital (MGH) AF study,1 the 
Rotterdam Study (RS),1 the Study of Health in Pomerania (SHIP),1 the Women’s Genome 
Health Study (WGHS),1 and the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER).2 Additional studies were described here: 
 
Discovery studies 
BioVU 
BioVU is the Vanderbilt University Medical Center's biorepository linked to de-identified  
electronic health records. BioVU operations3 and ethical oversight4 been described elsewhere. 
Briefly, DNA is collected from discarded blood samples remaining after routine clinical testing at 
Vanderbilt outpatient clinics in Nashville, Tennessee and surrounding areas, and is linked to a 
de-identified version of the patient's electronic health record termed the “Synthetic 
Derivative.” AF cases were defined as individuals who were aged >18 years, had an ICD-9 
diagnosis for AF or flutter (ICD-9: 427.3, 427.31, and 427.32), or a cardiologist diagnosis of AF as 
identified by a natural language processing tool from the unstructured free text of the ECG 
impression. In all instances, patients with a history of a heart transplant were excluded (Current 
Procedural Terminology: 33935, 3394, and 580; ICD-9: V42.1, 996.83).5  
 
LURIC 
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study is an ongoing prospective study 
of more than 3,300 individuals of German ancestry in whom cardiovascular and metabolic 
phenotypes (CAD, MI, dyslipidemia, hypertension, metabolic syndrome and diabetes mellitus) 
have been defined or ruled out using standardized methodologies in all study participants.184 
Inclusion criteria for LURIC were: German ancestry (limitation of genetic heterogeneity), clinical 
stability (except for acute coronary syndromes) and availability of a coronary angiogram. 
Exclusion criteria were: any acute illness other than acute coronary syndromes, any chronic 
disease where non-cardiac disease predominated and a history of malignancy within the last 
five years. Genome-wide analyses using the Affymetrix 6.0 have been completed in all 
participants. A 10-year clinical follow-up for total and cause specific mortality has been 
completed. 
 
MESA 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical 
cardiovascular disease (disease detected non-invasively before it has produced clinical signs and 
symptoms) and the risk factors that predict progression to clinically overt cardiovascular 
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disease or progression of the subclinical disease. The cohort is a diverse, population-based 
sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the 
recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 
percent Asian (predominantly of Chinese descent). Participants were recruited during 2000-
2002 from 6 field centers across the U.S. (at Wake Forest University; Columbia University; Johns 
Hopkins University; the University of Minnesota; Northwestern University, and the University of 
California – Los Angeles). All underwent anthropomorphic measurement and extensive 
evaluation by questionnaires at baseline, followed by 4 subsequent examinations at intervals of 
approximately 2-4 years. Age and sex were self-reported.  
 
ECGs were recorded in the supine position after a period of rest. MESA ECG data were collected 
using GE MAC 1200 electrocardiographs. Digitally collected ECGs were transferred via phone 
lines to the MESA ECG center (EPICARE). The ECGs were automatically processed by use of GE 
Marquette 12-SL software (2001 version), after visual inspection of the recordings for quality.  
 
Current AF at baseline was an exclusion criterion. Follow-up phone calls to study participants 
(every 9-12 months) were used to identify all hospitalizations. Medical records, including 
discharge diagnoses, were obtained for each hospitalization. Incident AF was defined by 
International Classification of Disease codes 427.31 or 427.32 (9th revision). In addition, new 
diagnoses of AF were identified at follow-up by the presence of AF or atrial flutter on a study 
ECG at Exam 5 (approximately 10 years after baseline). 
 
Further information can be found at: 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3 
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PREVEND 
The PREVEND cohort study was founded in 1997, and is an ongoing community-based cohort 
study including 8592 inhabitants of the city of Groningen, The Netherlands.6  PREVEND is 
investigating the natural course of microalbuminaria and its relation to renal and cardiovascular 
disease. Details of the protocol, AF ascertainment and covariate definitions have been 
described elsewhere (www.prevend.org). AF was ascertained if either atrial flutter or AF was 
present on a 12-lead ECG obtained at one of the three PREVEND follow-up visits, or at an 
outpatient visit or hospital admission in the two hospitals in the city of Groningen (University 
Medical Center Groningen and Martini Hospital). Systolic and diastolic blood pressures were 
calculated as the mean of the last two measurements of the two visits, using an automatic GE 
Dinamap XL Model 9300 series device. Hypertension was defined as systolic blood pressure 
>140 mmHg, diastolic blood pressure >90 mmHg, or use of antihypertensive drugs. Use of 
antihypertensive drugs was based on available information from the pharmacy prescription 
database. Body mass index (BMI) was calculated as the ratio of weight to height squared 
(kg/m2). Genotyping was performed using the Illumina CytoSNP12v2 array. Genotype calling 
was performed using GenomeStudio, and imputation was performed using Beagle with the 
HapMap release 22 CEU referent panel. Analyses were performed with Plink v1.07 and R.  
Replication studies 
BEAT-AF/GAPP 
The Basel Atrial Fibrillation Cohort Study (BEAT-AF) is a prospective observational, multicenter 
cohort study. Between 2010 and 2014, 1550 patients with documented AF were enrolled across 
7 centers in Switzerland. Exclusion criteria were the inability to sign informed consent and the 
presence of short transient forms of AF. At baseline, patients completed detailed 
questionnaires about personal, medical, nutritional and lifestyle factors, current AF symptoms 
and co-morbidities. Current medications were recorded. A resting 12-lead electrocardiogram 
(ECG) was recorded and all patients underwent venous blood sampling at the local study 
center, including DNA from leukocytes. Yearly follow-ups by mailed questionnaires and phone 
interviews were performed in all patients in order to collect similar information as at baseline 
and to obtain details about adverse events. 
 
Controls were enrolled from the ‘genetic and phenotypic determinants of blood pressure and 
other cardiovascular risk factors’ (GAPP) study, which is an ongoing prospective population-
based cohort study among healthy adults in the Principality of Liechtenstein. Between 2010 and 
2013, all inhabitants of the Principality of Liechtenstein aged between 25 and 41 years were 
invited and 2170 agreed to participate in the study. Main exclusion criteria were established 
cardiovascular disease, chronic kidney disease, diagnosed sleep apnea, a body mass index (BMI) 
> 35 kg/m2, intake of antidiabetic drugs or any other severe illness. Examinations included 
detailed assessment of personal, medical, lifestyle and nutritional factors, standardized 
assessment of weight, height and waist circumference, blood pressure measurement, 
electrocardiography, bioimpedance analysis, blood, urinary and genetic sampling, spirometry 
and sleep pulse oximetry with nasal flow measurement. Follow-up examinations are scheduled 
Genetic Interactions and Atrial Fibrillation 
Supplemental Material 
 
Page 7 of 18 
every 3-5 years. The detailed study design has previously been published ( 
http://www.ncbi.nlm.nih.gov/pubmed/23299990 ) 
 
FINCAVAS 
The purpose of the Finnish Cardiovascular Study (FINCAVAS) is to construct a risk profile - using 
genetic, haemodynamic and electrocardiographic (ECG) markers - of individuals at high risk of 
cardiovascular diseases, events and deaths. All patients scheduled for an exercise stress test at 
Tampere University Hospital, who gave informed consent to participate, were recruited 
between October 2001 and December 2007. The total number of participants was 4,567. In 
addition to repeated measurements of heart rate and blood pressure, digital high-resolution 
ECG at 500 Hz was recorded continuously during the entire exercise test, including the resting 
and recovery phases. About 20% of the patients were examined with coronary angiography. 
Genetic variations known or suspected to alter cardiovascular function or pathophysiology 
were analyzed to elucidate the effects and interactions of these candidate genes, exercise, and 
commonly used cardiovascular medications. 
 
Malmo Diet and Cancer Study (MDCS) 
MDCS is a community-based prospective epidemiologic cohort of middle-aged individuals from 
Southern Sweden.7 In total, 30,447 subjects attended a baseline exam in 1991-1996, when they 
filled out a questionnaire and underwent anthropometric and blood pressure measurements. 
Hypertension was defined as self-reported use of antihypertensive medications or measured 
blood pressure ≥140/90 mmHg. Prevalent or incident cases of atrial fibrillation (AF), heart 
failure and ischemic heart disease were ascertained from nation-wide hospital registers with 
high validity as described previously.8 Genome-wide genotyping of single nucleotide variants 
was performed using the Illumina Human Omni Express Exome BeadChip kit. Genotyping was 
performed in a nested case-cohort design, including a random subset of 7255 subjects with 
complete data and 876 cases with incident AF. Imputation was performed to genotypes in the 
1000 Genomes Project phase 1 using IMPUTE.  
 
UK Biobank 
Details of genotyping, imputation, and calculation of principal components of ancestry in the 
UK biobank interim dataset can be found on the UK biobank website 
(http://www.ukbiobank.ac.uk/). Briefly, samples were genotyped either by UK BiLEVE Axiom 
array (UKBL) or UK Biobank Axiom array (UKBB). Both arrays include ~800,000 SNPs and more 
than 95% of common marker contents are similar. Imputation was phased by modified version 
of SHAPEIT2 and imputed by IMPUTE2, using a combined panel of UK10K haplotype and 1000G 
phase 3 as the reference panel. All significant variants detected in the discovery study passed 
quality control filters in the UK biobank data (imputation quality info ≥ 0.4, variant missing rate 
< 5%, individual missing rate < 10%, and variant genotype probability > 0.9 in > 90% of the 
individuals). Variants were then transformed to hard-called genotypes (probability threshold ≥ 
0.9, minor allele frequency (MAF) ≥ 0.01, and missing rate per variant <5%). We used logistic 
regression to test the association between each hard-called variant and risk of AF using an 
additive genetic model, adjusting for baseline age, sex, array, and the first 5 principal 
Genetic Interactions and Atrial Fibrillation 
Supplemental Material 
 
Page 8 of 18 
components of ancestry. Quality control, transformation and analyses were performed by 
QCTOOL and Plink v1.90b. 
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Supplemental Table 1. Analysis-specific numbers of included autosomal SNPs and genomic inflation estimates by study sample. 
 
Abbreviations: λ, genomic inflation factor.
 Age Sex Body mass index Hypertension 
 ≤65 years >65 years     
Cohort N SNPs (λ) N SNPs (λ) N SNPs (λ) N SNPs (λ) N SNPs (λ) 
Incident           
AGES — — — — 2136078 0.995 2136115 1.060 2101296 1.033 
ARIC 2165687 0.987 — — 2179076 1.004 2179099 1.169 2179081 1.012 
CHS — — 2067494 1.045 2067674 1.027 2067674 1.121 2067674 1.021 
FHS — — 2144443 1.004 2144443 1.005 2144443 1.061 2144439 0.994 
MESA — — 2093768 1.024 2171564 1.039 2171941 1.061 2171884 1.033 
PREVEND — — — — 1859130 1.040 1859123 1.105 1858235 1.006 
PROSPER — — 2163841 1.014 2163841 0.998 2163841 1.004 2163841 1.006 
RS 2164948 1.022 2165443 1.20 2165273 1.002 2165437 0.992 2165217 1.008 
WGHS 2159805 1.023 2159805 1.001 — — 2159805 1.032 2159805 0.995 
Prevalent           
AFNET/KORA 2168049 1.017 — — 2168048 0.988 2168003 1.028 2168050 1.030 
AGES — — — — 2133548 0.998 2126844 1.033 2133550 1.060 
BioVU 660 — — — — 1658797 1.015 1660844 0.846 1625789 0.951 
BioVU o1 — — 1813638 1.021 1813587 1.008 1813746 0.991 1803269 0.984 
CCAF 2176365 1.036 2173984 1.027 2175987 1.001 2175951 1.014 2175987 1.024 
FHS — — 2144443 1.031 2144393 1.009 2143524 1.009 2144443 1.031 
LURIC 2169011 1.005 2169011 1.003 2169007 0.999 2169003 1.014 2163105 1.022 
MGH/MIGEN 2166720 1.004 — — 2167717 0.967 — — — — 
RS — — 2164958 1.021 2165408 1.011 2165435 1.019 2165315 1.000 
SHIP — — — — 2237384 1.036 2239095 1.075 2238479 1.033 
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Supplemental Table 2. Sixteen AF-associated loci reported in previous association studies. 
Locus SNP Closest gene 
Minor allele 
frequency (%) 
Relative risk 
 (95% CI) P Value Reference 
1q21 rs6666258 KCNN3 29.9 1.18 (1.13-1.23) 2.0x10-14 1 
1q24 rs3903239 PRRX1 44.7 1.14 (1.10-1.18) 9.1x10-11 1 
3p25 rs4642101 CAND2 35 1.10 (1.06-1.14) 9.8x10-9 2 
4q25 rs1448818 PITX2 25 1.12 (1.08-1.17) 1.6x10-8 9 
4q25 rs6817105 PITX2 13.1 1.64 (1.55-1.73) 1.8x10-74 1 
4q25 rs4400058 PITX2 9 1.28 (1.21-1.36) 2.2x10-16 9 
4q25 rs6838973 PITX2 44 1.11 (1.08-1.15) 6.0x10-9 9 
6q22 rs13216675 GJA1 31 1.10 (1.06-1.14) 2.2x10-8 2 
7q31 rs3807989 CAV1 40.4 0.88 (0.84-0.91) 9.6x10-11 1 
9q22 rs10821415 C9orf3 42.4 1.13 (1.08-1.18) 7.9x10-9 1 
10q22 rs10824026 SYNPO2L 15.8 0.85 (0.81-0.90) 1.7x10-8 1 
10q24 rs12415501 NEURL 16 1.18 (1.13-1.23) 6.5x10-16 2 
12q24 rs10507248 TBX5 27 1.12 (1.08-1.16) 5.7x10-11 2 
14q23 rs1152591 SYNE2 47.6 1.13 (1.09-1.18) 6.2x10-10 1 
15q24 rs7164883 HCN4 16.0 1.16 (1.10-1.22) 1.3x10-8 1 
16q22 rs2106261 ZFHX3 17.6 1.24 (1.17-1.30) 3.2x10-16 1 
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Supplemental Table 3. Details of study populations. 
Discovery Cohorts     
Cohort Country Study design AF diagnosis Hypertension Definition Reference 
AFNET/KORA Germany Case-Control ECG 
>140mmHg, or diastolic 
blood pressure >90mmHg, 
or use of antihypertensive 
medication for this 
purpose 
10,11
 
AGES Iceland Cohort ICD-10: I48 
Hypertension, either self 
reported from 
qustionnaire, derived from 
physiological 
measurements (systolic 
blood pressure, diastolic 
blood pressure ), or use of 
hypertension medications 
12
 
ARIC United States Cohort 
ECG at study visits, hospital discharge codes or 
death certificates (ICD-9 code 427.31 or 427.32, 
or ICD-10 code I48). 
SBP>=140, DBP>=90 or use 
of antihypertensive meds 
13,14
 
BioVU United States 
Cohort: hospital-based study 
(Biobank) 
>18 years and an ICD-9 diagnosis for AF or flutter 
(ICD-9: 427.3, 427.31, and 427.32), or a 
cardiologist diagnosis of AF as identified by a 
natural language processing tool from the 
unstructured free text of the ECG impression. In 
all instances, patients with a history of a heart 
transplant were excluded (Current Procedural 
Terminology: 33935, 3394, and 580; ICD-9: 
V42.1, 996.83) 
Hypertension was 
identified from the EHR 
using a multimodal 
algorithm using blood 
pressures, billing codes, 
medications, and text 
mentions of hypertension. 
3,5,15
 
CHS United States Cohort 
Annual CHS ECG or by ICD-9 code on a hospital 
discharge. 
SBP>=140, DBP>=90 or use 
of antihypertensive meds 
for treatment of high 
blood pressure 
16
 
CCFS United States Case-control ECG or medical report 
SBP>=140, DBP>=90 or 
history of hypertension 
1
 
FHS United States Cohort 
Cardiovascular hospital and outside records and 
ECG at all FHS examinations 
SBP>=140, DBP>=90 or use 
of antihypertensive meds 
17,18
 
LURIC Germany Cohort: hospital-based study ECG
 
or medical report 
SBP>=140, DBP>=90 or 
history of hypertension 
19
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MESA United States Cohort 
All interim hospital admissions, cardiovascular 
outpatient diagnoses, and deaths. More 
information is included in the cohort description. 
Self-reported treatment 
for hypertension or a 
systolic BP ≥140 mm Hg or 
diastolic BP ≥90 mm Hg 
20,21
 
MGH/MIGEN United States Cohort: hospital-based study ECG - 
22,23
 
PREVEND The Netherlands Cohort ECG 
Hypertension was defined 
as systolic blood pressure 
>140 mm Hg, diastolic 
blood pressure >90 mm 
Hg, or use of 
antihypertensive drugs 
6,24
 
PROSPER 
Ireland, 
Scotland, and 
the Netherlands 
Randomized, double-blind, 
placebo-controlled trial 
ECG 
systolic blood pressure 
was ≥ 140 mm Hg or the 
diastolic blood pressure 
was ≥ 90 mm Hg 
25
 
Rotterdam Study The Netherlands Cohort 
Study visit ECG, hospital discharge information, 
and general practitioner diagnoses. 
SBP ≥ 140 mmHg and/or 
DBP ≥ 90 mmHg or 
antihypertensive 
medication 
26,27
 
SHIP Germany Cohort Study visit ECG or tele-ecg 
SBP ≥ 140 mmHg and/or 
DBP ≥ 140 mmHg or 
antihypertensive 
medication 
28
 
WGHS United States Cohort ECG
 
or medical report 
History of hypertension ≥ 
140/90, defined as MD 
diagnosis at enrollment or 
run-in OR SBP ≥ 140 OR 
DBP ≥ 90 
29-31
 
Replication Cohorts    
Cohort Country Study design AF diagnosis Hypertension Definition Reference 
Beat-AF/ GAPP 
Switzerland / 
Liechtenstein 
Case-control ECG 
≥140/90 mmHg or use of 
BP lowering drugs 
32
 
FINCAVAS Finland Cohort: hospital-based study ECG, hospital discharge information 
≥140/90 mmHg or use of 
BP lowering drugs 
33
 
MDCS Sweden Case-control National register ≥140/90 
7
 
UK Biobank United Kingdom Cohort: Biobank 
Verbal interview, diagnosis codes, or procedure 
codes 
On anti-hypertensive 
medication at enrollment 
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Supplemental Table 4. Details regarding study genotyping and data analysis. 
Discovery Cohorts 
Study 
Genotypin
g platform 
Imputation 
software 
Imputation 
Backbone / 
NCBI Build 
Statistical 
software 
GWAS Statistical Analysis Covariates 
Robust variance 
estimator 
(Y/N) 
AFNET/KORA Published data
9
 ProbABEL, R Logistic regression Age, sex, 4 PCs Y 
AGES Published data
9
 ProbABEL, R 
Inc: Cox proportional hazard 
regression; Pre: Logistic regression 
Age, sex Y 
ARIC Published data
9
 ProbABEL, R Cox proportional hazard regression Age, sex, center N 
BioVU 
Human660
W-Quad 
BeadChip / 
HumanOm
ni1-Quad 
BeadChip 
SHAPE-
IT/IMPUTE
2 
1000G 
Phase 1 
integrated 
v3 panel 
/b37 
 
PLINK Logistic regression Age, sex, 2PCs N 
CHS Published data
9
 R Cox proportional hazard regression Age, sex, clinic N 
CCFS Published data
9
 ProbABEL, R Logistic regression Age, sex, 3 PCs + CAD Y 
FHS Published data
9
 R 
Inc: Cox proportional hazard 
regression; Pre: GEE 
Age, sex Y 
LURIC Published data
9
 ProbABEL Logistic regression Age, sex, 3 PCs Y 
MESA 
Affymetrix 
Genome-
Wide 
Human 
SNP Array 
6.0 
(Affymetrix
, Santa 
Clara, CA) 
IMPUTE2 
1,000 
Genomes 
Phase I 
integrated 
variant set 
(NCBI build 
37 / hg19) 
 
 
 
 
 
ProbABEL, R Logistic regression Age, sex, sites, 2PCs Y 
MGH/MIGEN Published data
9
 R Logistic regression Age, sex, 6 PCs N(age), Y(sex) 
PREVEND 
Illumina 
CytoNP12 
v2 
SHAPE-
IT/IMPUTE
2 
1000G 
Phase 1 
integrated 
v3 
panel/b37 
ProbABEL, R Logistic regression Age,sex, PC1-5 N 
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PROSPER Published data
9
 ProbABEL, R 
Inc: Cox proportional hazard 
regression 
Age, sex, PC 1-4 N 
Rotterdam Study Published data
9
 ProbABEL, R 
Inc: Cox proportional hazard 
regression; Pre: Logistic regression 
Age, sex N 
SHIP Published data
9
 ProbABEL Logistic regression age, sex Y 
WGHS Published data
9
 ProbABEL Cox PH regression (incident AF) 
age, eigenvector E2 
for HXHTN interaction 
only  
N(age), Y(sex, bmi) 
Replication Cohorts 
Study 
Genotypin
g platform 
Imputation 
software 
Imputation 
Backbone / 
NCBI Build 
Statistical 
software 
GWAS Statistical Analysis Covariates 
Robust variance 
estimator 
(Y/N) 
Beat-AF/GAPP 
Illumina 
HumanCor
eExome 
SHAPEIT 
v2.r790 + 
IMPUTE 
v.2.3.2 
Build 37 R Logistic regression Sex, 10 PCs N 
FINCAVAS 
Illumina 
Metabochi
p and 
Human 
CoreExome 
SHAPEIT 
v2, IMPUTE 
v2.3.0 
1000G 
Phase 1 
integrated 
v3 panel 
/b37 
R Logistic regression Age, sex and 10 PCs N 
MDCS 
Illumina 
Human 
Omni 
Express 
Exome 
BeadChip 
IMPUTE 
NCBI Build 
37 
R Cox proportional hazard regression Age, sex and 10 PCs N 
UK Biobank 
UK Bileve 
or UK 
Biobank 
Axiom 
Array 
IMPUTE 
Combined 
1000G and 
UK10K / 
Hg37 
R Logistic regression 
Age, sex, and first 5 
PCs 
N 
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Supplemental Figure 1a-1d. Quantile-quantile plots for each genetic interaction analysis on chromosomes 1-
22. 
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Supplemental Figure 2. Regional association plot for genome-wide significant SNP by BMI interaction on 
chromosome 10. 
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